FCH
ABBV icon

Freestone Capital Holdings’s AbbVie ABBV Stock Holding History

Freestone Capital Holdings’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-400
Closed -$91.4K – 572
2025
Q4 		$91.4K Buy
+400
New +$91.1K ﹤0.01% 535

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Freestone Capital Holdings's ABBV Position: Q1 2026 in Review

Freestone Capital Holdings increased its AbbVie (ABBV) stake by 1.1% in Q1 2026, buying an estimated $175K and bringing the position to 70,002 shares worth $15.2M. The position accounts for 0.46% of the portfolio, ranked #33.

Freestone Capital Holdings first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.1M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Freestone Capital Holdings held 70,002 shares of AbbVie worth $15.2M as of Q1 2026.
  • Freestone Capital Holdings bought 788 AbbVie shares in Q1 2026, an estimated $175K.
  • AbbVie made up 0.46% of Freestone Capital Holdings's portfolio in Q1 2026, its #33 holding.
  • Freestone Capital Holdings first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Freestone Capital Holdings's AbbVie position peaked at $16.1M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Freestone Capital Holdings's 13F filing for Q1 2026, filed 13 May 2026.